Melanoma Combos Get Mixed Reception From German HTA Body
Executive SummaryGermany’s IQWiG says Mekinist plus Tafinlar offers a “considerable” added benefit in melanoma after surgery, but Braftovi plus Mektovi has not shown an additional benefit over comparator therapy in unresectable or metastatic melanoma.
You may also be interested in...
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Life science companies will be pleased to hear that the European Parliament is pressing for close cooperation between the UK and the EU in the area of medicines regulation.